Coiled Therapeutics plc

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.coiledtx.com/

Country

🇬🇧 United Kingdom

Exchange

LSE

Coiled Therapeutics plc, a clinical-stage oncology company develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and globally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer

A STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials. The company is based in London, United Kingdom.

Key Stats

52-Week Range

£0.00£30.00

BetaN/A

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-0.22

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.